Sinopep-Allsino Biopharmaceutical Co. Ltd. A Net Asset Quality Index
Sinopep-Allsino Biopharmaceutical Co. Ltd. A net asset quality index. Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Net Asset Quality Index of 43.9% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥7.07 Billion minus total liabilities of CN¥3.97 Billion yields net assets of CN¥3.10 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Sinopep-Allsino Biopharmaceutical Co. Lt (688076) shareholders funds for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
Net asset quality index of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025. This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the index stands at 43.9%, representing net assets of CN¥3.10 Billion against total assets of CN¥7.07 Billion CNY. Check 688076 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Net Asset Quality Index by Year (2013–2025)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 688076 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 44.5% | CN¥3.00 Billion | CN¥6.74 Billion | CN¥3.74 Billion | ▼ -8.3 pp |
| 2024 | 52.8% | CN¥2.68 Billion | CN¥5.08 Billion | CN¥2.40 Billion | ▼ -8.9 pp |
| 2023 | 61.7% | CN¥2.19 Billion | CN¥3.55 Billion | CN¥1.36 Billion | ▼ -14.6 pp |
| 2022 | 76.3% | CN¥1.92 Billion | CN¥2.52 Billion | CN¥597.41 Million | ▼ -8.7 pp |
| 2021 | 85.0% | CN¥1.81 Billion | CN¥2.13 Billion | CN¥318.14 Million | ▲ +15.8 pp |
| 2020 | 69.2% | CN¥966.02 Million | CN¥1.40 Billion | CN¥429.55 Million | ▲ +1.8 pp |
| 2019 | 67.4% | CN¥838.98 Million | CN¥1.24 Billion | CN¥405.54 Million | ▼ -7.3 pp |
| 2018 | 74.7% | CN¥785.38 Million | CN¥1.05 Billion | CN¥265.47 Million | ▲ +22.2 pp |
| 2017 | 52.5% | CN¥321.20 Million | CN¥611.47 Million | CN¥290.27 Million | ▲ +30.7 pp |
| 2016 | 21.8% | CN¥34.95 Million | CN¥160.11 Million | CN¥125.16 Million | ▼ -15.4 pp |
| 2015 | 37.3% | CN¥73.32 Million | CN¥196.67 Million | CN¥123.35 Million | ▲ +51.4 pp |
| 2014 | -14.2% | CN¥-21.47 Million | CN¥151.58 Million | CN¥173.05 Million | ▼ -16.4 pp |
| 2013 | 2.2% | CN¥3.69 Million | CN¥166.81 Million | CN¥163.12 Million | — |